Abstract
To formulate Functional Assessment of Cancer Therapy-Meningioma (FACT-MNG), a web-based tumor site-specific outcome instrument for assessing intracranial meningioma patients following surgical resection or stereotactic radiosurgery. We surveyed the relevant literature available on intracranial meningioma surgery and subsequent outcomes (38 papers), making note of which, if any, QOL/outcome instruments were utilized. None of the surgveyed papers included QOL assessment specific to tumor site. We subsequently developed questions that were relevant to the signs and symptoms that characterize each of 11 intracranial meningioma sites, and incorporated them into a modified combination of the Functional Assessment of Cancer Therapy-Brain (FACT-BR) and SF36 outcome instruments, thereby creating a new tumor site-specific outcome instrument, FACT-MNG. With outcomes analysis of surgical and radiosurgical treatments becoming more important, measures of the adequacy and success of treatment are needed. FACT-MNG represents a first effort to formalize such an instrument for meningioma patients. Questions specific to tumor site will allow surgeons to better assess specific quality of life issues not addressed in the past by more general questionnaires.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Outcomes and Quality of Life (QOL) assessment instruments are important for assessing the results of surgical and radiosurgical treatment, as well as comparing results across studies [16]. Many of these instruments assess QOL but not in a manner that addresses the CNS symptoms/signs of specific tumor sites. This becomes increasingly relevant when dealing with tumors that tend to arise in specific intracranial locations which can lead to distinct symptom complexes with unique effects on QOL that can be overlooked by less specific QOL instruments. Recognizing these location-specific symptom complexes allow us the opportunity to personalize the QOL assessment towards distinct patient groups.
Meningiomas comprise one such class of location-specific intracranial tumors [31]. Accounting for some 20% of intracranial tumors, they are generally histologically benign and slow growing, but may become locally invasive. Due to the risk of tumor growth and development of focal neurological deficits from mass effect, standard treatment usually consists of surgical resection or stereotactic radiosurgery.
QOL assessment provides information regarding efficacy of surgical/radiosurgical treatment and may serve as an important decision-making tool for patients and physicians who are weighing the risks and benefits of brain surgery, especially if their meningioma is of the benign variety. While there are a variety of outcome assessment tools currently available, they vary widely in terms of scope (post-surgery QOL, post-cancer therapy QOL, post-brain surgery QOL, etc.), and none are currently location-specific. Currently, the instrument most accurately targeted at assessing QOL following brain tumor resection is the validated Functional Assessment of Cancer Therapy-Brain (FACT-BR) [22, 23, 40].
The location-specific nature of clinical symptoms and signs of intracranial meningiomas provides an opportunity for an even more targeted QOL assessment; one that takes into account site-specific symptoms [42]. This would allow for a more detailed examination of an individual patient’s QOL based on tumor site and pre/post-surgery signs and symptoms. With these goals in mind, FACT-MNG was created. An important part of developing such an instrument was making it available freely in a web based platform so that patients could access the questionnaire on regular set intervals without the need for direct physician contact or instruction. The VisionTree Optimal Care™ (VTOC) secure web-based portal allows for patients to enter the site through self-registration and complete the FACT-MNG electronically. Upon registration, the patient automatically receives an email with their secure login information providing ongoing access to the survey. VTOC includes full reporting/tracking capabilities to query the data which can be exported to Excel for additional analysis.
Methods
Initial data was gathered by way of reviewing relevant literature (via PubMed) which discussed and examined intracranial meningioma surgical therapy as well as subsequent outcomes. With 38 papers [1–15, 17–22, 24–30, 32–41] in hand meeting our search criteria, we reviewed the assessment instruments utilized in each. While all of the papers included outcomes, when it came to QOL assessment, 2 of the 38 used SF36 [3, 19, 39] others used FACT-BR [5, 22, 40], and 8 used a more basic patient functionality-oriented Karnofsky Performance Status (KPS) comparison [10, 13, 28, 32, 34, 36, 37], and less than half (15 of 38 papers) utilized any QOL instrument at all (FACT-BR, SF36, KPS Scale, or some other instrument). None of the papers utilized site-specific questions.
Results and discussion
To address the issue of site specificity, we created FACT-MNG (Functional Assessment of Cancer Therapy-Meningioma), an amalgamation of FACT-BR, SF36, and newly formulated questions addressing tumor site-specific signs and symptoms. Specifically, we started with FACT-BR as our base and added questions from SF36 that were more detailed in ascertaining the patient’s physical capabilities (e.g., ability to perform light, mild, or strenuous activity without difficulty) (Table 1). Our most significant modification was the creation and inclusion of questions that were relevant to the signs and symptoms that characterize one of 11 tumor sites: olfactory groove, tuberculum sella, optic nerve sheath, sphenoid wing, cavernous sinus, parasagittal, tentorium cerebelli, petroclival region, cerebellopontine angle, cerebellar convexity, and foramen magnum (Table 2, 3).
Following its creation, FACT-MNG was converted into a web-based format (currently available for patients/physicians to download for free at https://www.optimalcare.com. In addition to the benefits of offering FACT-MNG digitally (streamlined data collection, storage, and analysis), the dynamic delivery offered by a web-based application allows patients to only answer questions pertinent to their tumor’s site. At UCSF we plan to introduce patients to the web site and questionnaire with a small business card containing the web site URL and suggested time interval for assessment post-operatively at 3, 6, 12, 18, 24, 36, 48, 60, and 72 months. Any additional intervention will re-start the assessment clock for the initial intervention and begin a new follow-up session. The VTOC system can be configured to release the FACT-MNG into the patient’s portal at the specific time points noted above. An email alert is automatically sent to remind the patient to login and complete the survey at each time interval. The process is fully automated within VTOC using templates and calendar reminders to ensure accuracy and compliance. A subset of patients may not be proficient with or have access to computers, either due to educational differences, socioeconomic status, or as a result of their disease process and/or treatment. For these selected patients, notifications by mail can be utilized.
Conclusion
With QOL assessment becoming increasingly important as an information, education and –outcomes assessment tool for both physicians and patients, relying on an outcome instrument too general in scope may leave more detailed, but nonetheless pertinent, issues unexplored and unmeasured. While FACT-BR has been validated as an assessment tool pertaining to brain tumors in general, those tumors which associated with characteristic site-specific signs and symptoms readily lend themselves towards QOL assessment with an even further refined scope. Intracranial meningiomas offer one such opportunity and, on account of their comprising almost one-fifth of all intracranial tumors, warrant the development of an outcome instrument with a narrower scope.
This instrument is not yet clinically validated. Further examination of FACT-MNG should revolve around qualifying its validity as compared to the outcome assessment provided by other QOL instruments (most notably FACT-BR) following meningioma surgical therapy. The authors of this paper plan to investigate the use of this instrument in a prospective fashion on their patient population and report on the results at a future date.
References
Abdel-Aziz KM, Froelich SC, Dagnew E et al (2004) Large sphenoid wing meningiomas involving the cavernous sinus: conservative surgical strategies for better functional outcomes. Neurosurgery 54:1375–1383; discussion 1383–1374
Borba LA, de Oliveira JG, Giudicissi-Filho M et al (2009) Surgical management of foramen magnum meningiomas. Neurosurg Rev 32:49–58; discussion 59–60
Boulton MR, Cusimano MD (2003) Foramen magnum meningiomas: concepts, classifications, and nuances. Neurosurg Focus 14:e10
Bret P, Guyotat J, Madarassy G et al (2000) Tentorial meningiomas. report on twenty-seven cases. Acta Neurochir (Wien) 142:513–526
Brown PD, Maurer MJ, Rummans TA et al (2005) A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 57:495–504; discussion 495–504
Chan RC (1984) Thompson GB (1984) Morbidity, mortality, and quality of life following surgery for intracranial meningiomas A retrospective study in 257 cases. J Neurosurg 60:52–60
Chi JH, Parsa AT, Berger MS et al (2006) Extended bifrontal craniotomy for midline anterior fossa meningiomas: minimization of retraction-related edema and surgical outcomes. Neurosurgery 59:ONS426–433; discussion ONS433–424
Dave SP, Bared A, Casiano RR (2007) Surgical outcomes and safety of transnasal endoscopic resection for anterior skull tumors. Otolaryngol Head Neck Surg 136:920–927
de Divitiis E, Esposito F, Cappabianca P et al (2008) Tuberculum sellae meningiomas: high route or low route? A series of 51 consecutive cases. Neurosurgery 62:556–563; discussion 556–563
De Jesus O, Sekhar LN, Parikh HK et al (1996) Long-term follow-up of patients with meningiomas involving the cavernous sinus: recurrence, progression, and quality of life. Neurosurgery 39:915–919; discussion 919–920
Deinsberger R, Tidstrand J, Sabitzer H et al (2004) LINAC radiosurgery in skull base meningiomas. Minim Invasive Neurosurg 47:333–338
Drummond KJ, Zhu JJ, Black PM (2004) Meningiomas: updating basic science, management, and outcome. Neurologist 10:113–130
Dufour H, Muracciole X, Metellus P et al (2001) Long-term tumor control and functional outcome in patients with cavernous sinus meningiomas treated by radiotherapy with or without previous surgery: is there an alternative to aggressive tumor removal? Neurosurgery 48:285–294; discussion 294–286
Gardner PA, Kassam AB, Thomas A et al (2008) Endoscopic endonasal resection of anterior cranial base meningiomas. Neurosurgery 63:36–52; discussion 52–34
Gijtenbeek JM, Hop WC, Braakman R et al (1993) Surgery for intracranial meningiomas in elderly patients. Clin Neurol Neurosurg 95:291–295
Giovagnoli AR, Tamburini M, Boiardi A (1996) Quality of life in brain tumor patients. J Neurooncol 30:71–80
Hamm K, Henzel M, Gross MW et al (2008) Radiosurgery/stereotactic radiotherapy in the therapeutical concept for skull base meningiomas. Zentralbl Neurochir 69:14–21
Hasegawa T, Kida Y, Yoshimoto M et al (2007) Long-term outcomes of Gamma Knife surgery for cavernous sinus meningioma. J Neurosurg 107:745–751
Honeybul S, Neil-Dwyer G, Lang DA et al (2001) Sphenoid wing meningioma en plaque: a clinical review. Acta Neurochir (Wien) 143:749–757; discussion 758
Jan M, Bazeze V, Saudeau D et al (1986) Outcome of intracranial meningioma in adults. Retrospective study of a medicosurgical series of 161 meningiomas. Neurochirurgie 32:129–134
Jensen AW, Brown PD, Pollock BE et al (2005) Gamma knife radiosurgery of radiation-induced intracranial tumors: local control, outcomes, and complications. Int J Radiat Oncol Biol Phys 62:32–37
Kalkanis SN, Quinones-Hinojosa A, Buzney E et al (2000) Quality of life following surgery for intracranial meningiomas at Brigham and Women’s Hospital: a study of 164 patients using a modification of the functional assessment of cancer therapy-brain questionnaire. J Neurooncol 48:233–241
Kan P, Cusimano M (2006) Validation of a quality-of-life questionnaire for patients with pituitary adenoma. Can J Neurol Sci 33:80–85
Kim MS, Park K, Kim JH et al (2008) Gamma knife radiosurgery for orbital tumors. Clin Neurol Neurosurg 110:1003–1007
Kondziolka D, Flickinger JC, Perez B (1998) Judicious resection and/or radiosurgery for parasagittal meningiomas: outcomes from a multicenter review. Gamma Knife Meningioma Study Group. Neurosurgery 43:405–413; discussion 413–404
Kondziolka D, Mathieu D, Lunsford LD et al (2008) Radiosurgery as definitive management of intracranial meningiomas. Neurosurgery 62:53–58; discussion 58–60
Krupp W, Klein C, Koschny R et al (2009) Assessment of neuropsychological parameters and quality of life to evaluate outcome in patients with surgically treated supratentorial meningiomas. Neurosurgery 64:40–47; discussion 47
Levine ZT, Buchanan RI, Sekhar LN et al (1999) Proposed grading system to predict the extent of resection and outcomes for cranial base meningiomas. Neurosurgery 45:221–230
Li X, Liu M, Liu Y et al (2007) Surgical management of Tuberculum sellae meningiomas. J Clin Neurosci 14:1150–1154
Linskey ME, Davis SA, Ratanatharathorn V (2005) Relative roles of microsurgery and stereotactic radiosurgery for the treatment of patients with cranial meningiomas: a single surgeon 4-year integrated experience using both modalities. J Neurosurg (suppl) 102:59–70
Mariniello G, Maiuri F, Strianese D et al (2008) Spheno-orbital meningiomas: surgical approaches and outcome according to the intraorbital tumor extent. Zentralbl Neurochir 69:175–181
McDermott MW, Wilson CB (1996) Meningiomas. In: Youmans J (ed) Neurological Surgery. W.B. Saunders Company, Philadelphia, pp 2782–2825
Natarajan SK, Sekhar LN, Schessel D et al (2007) Petroclival meningiomas: multimodality treatment and outcomes at long-term follow-up. Neurosurgery 60:965–979; discussion 979–981
O’Dell MW, Barr K, Spanier D et al (1998) Functional outcome of inpatient rehabilitation in persons with brain tumors. Arch Phys Med Rehabil 79:1530–1534
Park CK, Jung HW, Kim JE et al (2006) The selection of the optimal therapeutic strategy for petroclival meningiomas. Surg Neurol 66:160–165; discussion 165–166
Raco A, Bristot R, Domenicucci M et al (1999) Meningiomas of the tuberculum sellae. Our experience in 69 cases surgically treated between 1973 and 1993. J Neurosurg Sci 43:253–260; discussion 260–252
Roser F, Ebner FH, Ritz R et al (2007) Management of skull based meningiomas in the elderly patient. J Clin Neurosci 14:224–228
Sachsenheimer W, Piotrowski W, Bimmler T (1992) Quality of life in patients with intracranial tumors on the basis of Karnofsky’s performance status. J Neurooncol 13:177–181
Spektor S, Valarezo J, Fliss DM et al (2005) Olfactory groove meningiomas from neurosurgical and ear, nose, and throat perspectives: approaches, techniques, and outcomes. Neurosurgery 57:268–280; discussion 268–280
van Nieuwenhuizen D, Klein M, Stalpers LJ et al (2007) Differential effect of surgery and radiotherapy on neurocognitive functioning and health-related quality of life in WHO grade I meningioma patients. J Neurooncol 84:271–278
Weitzner MA, Meyers CA, Gelke CK et al (1995) The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75:1151–1161
Zachenhofer I, Wolfsberger S, Aichholzer M et al (2006) Gamma-knife radiosurgery for cranial base meningiomas: experience of tumor control, clinical course, and morbidity in a follow-up of more than 8 years. Neurosurgery 58:28–36; discussion 28–36
Acknowledgments
The authors thank Meningioma Mommas for their financial support with this project and Vision Tree Software for their role in developing FACT-MNG into a web-based application.
Open Access
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Zlotnick, D., Kalkanis, S.N., Quinones-Hinojosa, A. et al. FACT-MNG: tumor site specific web-based outcome instrument for meningioma patients. J Neurooncol 99, 423–431 (2010). https://doi.org/10.1007/s11060-010-0394-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-010-0394-3